Bernard De Bruyne.

Pim A.L . Tonino, M.D., Bernard De Bruyne, M.D., Ph.D., Nico H.J. Pijls, M.D., Ph.D., Uwe Siebert, M.D., M.P.H., Sc.D., Fumiaki Ikeno, M.D., Marcel van `t Veer, M.Sc., Volker Klauss, M.D., Ph.D., Ganesh Manoharan, M.D.D., Ph.D., Keith G. Oldroyd, M.D., Peter N. Ver Lee, M.D., Philip A. MacCarthy, M.D., Ph.D., and William F. Fearon, M.D. For the FAME Study Investigators: Fractional Movement Reserve versus Angiography for Guiding Percutaneous Coronary Intervention The presence of myocardial ischemia can be an important risk factor for a detrimental clinical outcome.1-3 Revascularization of stenotic coronary lesions that induce ischemia may improve a patient’s functional status and outcome.3-5 For stenotic lesions that do not induce ischemia, however, the advantage of revascularization is less clear, and medical therapy alone may very well be effective equally.6,7 With the introduction of drug-eluting stents, the %age of patients with multivessel coronary artery disease in whom percutaneous coronary intervention is performed has increased.8,9 Because drug-eluting stents are expensive and are associated with potential late complications, their appropriate use is crucial.10,11 However, in patients with multivessel coronary artery disease, determining which lesions cause ischemia and warrant stenting could be difficult.

The Centers for Medicare and Medicaid Solutions have recently urged condition Medicaid directors to supply coverage of the drugs for the 6.3 million people who are eligible for prescription help under the Medicaid and Medicare applications, but only if says recognize, will they continue steadily to get federal coordinating funds when they pay for benzodiazepine.. 1.7 million will be anxious when Medicare coverage of anxiety medicines ceases When the U.S. Government’s new prescription drug benefit begins next yr a category of drugs commonly used to treat anxiety, seizures and insomnia will never be included.